Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK4418959 · 1 trial · 5 indications
ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose escalation of GSK4418959 monotherapy | EXPERIMENTAL | Participants will receive GSK4418959 as monotherapy. |
| Part 2: Dose expansion of GSK4418959 monotherapy | EXPERIMENTAL | Participants will receive GSK4418959 as monotherapy. |
| Part 3: Dose escalation of GSK4418959 plus PD-1 inhibitor | EXPERIMENTAL | Participants will receive GSK4418959 plus PD-1 inhibitor. |
| Name | Type | Description |
|---|---|---|
| GSK4418959 | DRUG | GSK4418959 will be administered. |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor will be administered. |
Inclusion Criteria: Parts 1, 2, and 3 inclusion criteria: * Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor * Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)...
GSK4418959 is an investigational small molecule being developed for the treatment of solid tumors, including colorectal cancer, colon cancer, rectal cancer, and endometrial cancer. It is currently in Phase 1 clinical development for these oncology indications.
GSK4418959 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and effectiveness of this investigational drug.
GSK4418959 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, pharmacokinetics, and preliminary effectiveness in patients with solid tumors.
GSK4418959 is being studied in a Phase 1 clinical trial registered as NCT06710847. This trial investigates the drug alone or in combination with other anti-cancer agents in participants with solid tumors, including colorectal, colon, rectal, and endometrial cancers. The trial is active but not recruiting participants.
GSK4418959 is a small molecule drug. Its specific molecular target has not been disclosed in the available information, so its exact mechanism of action is not publicly detailed. It is being studied for its potential anti-cancer effects in solid tumors.